NCT04020185: Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with HR+ breast cancer, Patients with known untreated brain metastases or treated brain metastases that are unstable

Comments are closed.

Up ↑